Text Size
171 studies found for:    anti CD-20 antibodies

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
Condition: Lymphoma
Interventions: Drug: Fludarabine;   Drug: Novantrone;   Drug: Decadron;   Drug: Rituximab;   Drug: Interferon;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Bleomycin;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Ara-C;   Drug: Methyl-Prednisolone;   Drug: Procarbazine;   Drug: Prednisone
2 Completed Anti-CD20 Antibody Therapy for Sjogren's Syndrome
Condition: Sjogren's Syndrome
Intervention: Drug: Rituximab
3 Active, not recruiting Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia
Condition: Anemia, Hemolytic, Autoimmune
Interventions: Drug: prednisolone + mabthera;   Drug: Prednisolone
4 Active, not recruiting B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome
Conditions: Chronic Fatigue Syndrome;   Myalgic Encephalomyelitis
Intervention: Drug: Rituximab
5 Recruiting B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome
Conditions: Chronic Fatigue Syndrome;   Myalgic Encephalomyelitis
Intervention: Drug: Rituximab
6 Active, not recruiting
Has Results 		HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab
Condition: Lymphoma, Follicular
Intervention: Drug: Ofatumumab
7 Completed Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)
Condition: Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)
Intervention: Drug: Rituximab
8 Recruiting Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome
Conditions: Chronic Fatigue Syndrome;   Myalgic Encephalomyelitis
Intervention: Drug: Etanercept
9 Completed
Has Results 		HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
Condition: Leukaemia, Lymphocytic, Chronic
Intervention: Drug: ofatumumab
10 Completed Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: hA20-humanized anti-CD20 antibody
11 Recruiting Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
Conditions: Purpura, Thrombocytopenic, Idiopathic;   Autoimmune Thrombocytopenic Purpura;   Purpura, Thrombocytopenic, Autoimmune
Intervention: Biological: veltuzumab
12 Completed Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's Lymphoma
Conditions: Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: vincristine sulfate;   Drug: prednisone;   Biological: rituximab;   Other: laboratory biomarker analysis
13 Completed Anti-CD20 in Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Intervention: Drug: Rituximab
14 Completed Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: filgrastim;   Biological: rituximab;   Drug: CHOP regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate
15 Unknown † Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine;   Biological: sargramostim
16 Completed Rituximab in Treating Patients With Hodgkin's Lymphoma
Conditions: Lymphoma;   Hodgkin Lymphoma (Category)
Intervention: Drug: Rituximab
17 Active, not recruiting
Has Results 		Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Ofatumumab 500mg;   Drug: Ofatumumab 1000mg;   Drug: Fludarabine;   Drug: Cyclophosphamide
18 Terminated
Has Results 		Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
Conditions: Brain and Central Nervous System Tumors;   Drug/Agent Toxicity by Tissue/Organ;   Lymphoma;   Thrombocytopenia
Interventions: Drug: Rituxan;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Etoposide phosphate;   Drug: Carboplatin;   Drug: Sodium thiosulfate;   Drug: Neupogen;   Drug: Neulasta;   Drug: Cytarabine
19 Unknown † FCM Versus R-FCM Followed by R-Maintenance or Observation Only
Conditions: Lymphoma, Follicular;   Lymphoma, Low-Grade;   Lymphoma, Intermediate-Grade
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mitoxantrone;   Drug: Rituximab;   Procedure: chemotherapy: FCM;   Procedure: chemotherapy: R-FCM;   Procedure: maintenance therapy: Rituximab
20 Completed Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia
Conditions: Anemia, Aplastic;   Red-Cell Aplasia, Pure;   Anemia, Diamond-Blackfan
Intervention: Drug: Rituximab (Rituxan)
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years